Search

Your search keyword '"Henghui Zhang"' showing total 45 results

Search Constraints

Start Over You searched for: Author "Henghui Zhang" Remove constraint Author: "Henghui Zhang" Publisher american society of clinical oncology (asco) Remove constraint Publisher: american society of clinical oncology (asco)
45 results on '"Henghui Zhang"'

Search Results

1. Germline HLA-B evolutionary divergence to influence efficacy of immune checkpoint blockade therapy in gastrointestinal cancer

2. Features in genomics and tumor immune microenvironment in NSCLC treated with neoadjuvant PD-1 blockade

Catalog

Books, media, physical & digital resources

3. Molecular subtypes of pancreatic adenocarcinoma stratified based on copy number variation profile

4. Association of HLA class I genotype with outcomes of gastrointestinal cancer patients with immunotherapy

5. The association of CD8+ T-cell infiltration and PD-L1 expression with prognosis of Chinese pulmonary large cell neuroendocrine carcinoma

6. A pilot trial of multiple-TSA-specific adoptive immune cell (MAIC) as adjuvant therapy in gastrointestinal cancer

7. Application of MammaPrint test on Chinese patient with breast cancer

8. The mutational pattern of homologous recombination (HR) related genes and its relevance to response to immunotherapy in gastric cancer

9. Distinct transcriptional profiles in plasma exosomes associated with recurrence of nasopharyngeal carcinoma patients with standard treatment

10. PD-1 or PD-L1 co-localizes with immune cells for prediction of prognosis in non-small cell lung cancer

11. A risk scoring system to predict overall survival for patients with liver cancer

12. Effect of TP53 mutation on antitumor immunity and responsiveness to immunotherapy in colorectal cancer

13. The mutation of homologous recombination repair genetics is a potential biomarker for immunotherapy in microsatellite stable colon cancer

14. Mutation of DNA damage repair genes confers an immune-privileged tumor microenvironment in colorectal cancer with a prognostic value

15. Transcriptional profile of immune microenvironment and their prediction role for the prognosis of esophageal squamous cell carcinoma

16. Association of high copy number instability (CNI) score with prognosis in patients with gastric cancer after surgical resection

17. The mutational profile analysis of different response to neoadjuvant chemoradiation therapy in local advanced esophageal squamous cell cancer patients

18. The mutational profile analysis of extramural vascular invasion in rectal cancer

19. Genetic characteristics of lung metastasis and liver metastasis from left-sided colorectal cancer with microsatellite stability

20. Transcriptional characterization of microenvironment and their prediction role for the prognosis of hepatocellular carcinoma after surgery

21. Transcriptional characterization of immune microenvironment and their prediction role for the prognosis of local advanced lung adenocarcinoma

22. The molecular and immune characteristics, antitumor activity of crizotinib in non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping alterations

23. Burden of copy number alterations predicts outcomes in immune checkpoint blockade treated gastrointestinal cancer patients

24. Association of the ratio of CD8+ and CD163+ lymphocytes with clinical outcome in hepatocellular carcinoma

25. Prediction of hepatocellular carcinoma patient survival using machine learning classification rules

26. The cross talk between the molecular alterations and tumor immunity in the microenvironment in non-small-cell lung carcinoma

27. Tumor copy number alteration (CNA) burden as a prognostic factor for overall survival in Chinese gastric cancers

28. A RNA signature predicts outcomes in immune checkpoint blockade treated gastrointestinal cancer patients

29. Copy number instability (CNI) combined with CA19-9 as a biomarker for postoperative prognostic prediction of pancreatic cancer

30. Tracking the tumor evolution of patients with recurrence of ipsilateral breast tumor

31. The mutational landscape of MSI-H and MSS colorectal cancer

32. The mutational landscape of circulating cell-free DNA to identify neoadjuvant chemotherapy response in colorectal cancer patients

33. The mutational landscape of circulating cell free DNA in patients with colorectal adenoma and carcinoma

34. The mutational landscape of circulating cell free DNA in patients with esophageal squamous cell carcinoma response and non-response to neoadjuvant chemotherapy

35. Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers

36. Detection of early recurrence in HCC patients after TACE treatment with plasma cfDNA

37. Comparative genomic profiling of distant metastatic and nondistant metastatic lung adenocarcinoma

38. EGFR and ERBB2 to determine the metastatic status of mediastinal lymph nodes in lung adenocarcinomas harbouring EGFR mutation

39. Differences in small cell lung cancer genetic profile between disease progression (PD) and partial remission (PR) patients after the standard first-line chemotherapy

40. PD-L1 expression and TMB status in newly diagnosed metastatic non-small cell lung cancer and their effect on prognosis after EGFR-TKI or platinum-based chemotherapy

41. PD-L1 expression of 742 newly diagnosed advanced respiratory and digestive system tumours in China based on SP142 assay

42. Molecular analysis of cell-free DNA to identify distinct molecular mutational burden and its effect on first-line chemotherapy in patients with NSCLC from a phase III trial

43. Prognostic value of a 12-gene signature in platinum-based chemotherapy treated SCLC

44. Detection of tumor-derived DNA mutations in cerebrospinal fluid of patients with primary or metastatic brain tumors

45. Research on the diversity of T cell receptor repertoire in the process of malignant transformation of HBV chronic infection